WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, announced that newly published research has reaffirmed the ability of catheters protected with ARROWg+ard® Technology to reduce both bloodstream infections and direct costs associated with treating those infections.1
The ARROW® CVC with ARROWg+ard® Technology outperformed the unprotected CVC in both infection reduction and total cost per patient. Within the study, the protected catheter achieved a zero infection rate per 1,000 catheter days. In contrast, the unprotected device was associated with a much higher CRBSI rate of 8.61/1,000 catheter days (7.4% of cases). The results were statistically significant. Additionally, the antimicrobial protected catheter was also associated with prolonged CRBSI-free time compared to the unprotected catheter, including dwell times of up to 25 days without a bloodstream infection.
Help employers find you! Check out all the jobs and post your resume.
